Treating PsO with adalimumab and concomitant methotrexate has no difference in effectiveness and persistence when compared to adalimumab monotherapy.

PsO patients with low BSA involvement may experience similar QoL and disease burden as patients with high BSA.

Researchers have identified specific risk factors for anxiety and depression in AD patients.

Guselkumab is effective in treating moderate-to-severe scalp psoriasis in patients with Fitzpatrick Skin Types IV through VI.

Patients with GPP have a five times higher risk of all-cause mortality at one year than those without GPP.

Pediatric patients with HS have an increased prevalence of chronic medical and psychiatric comorbidities.

Stigma around alopecia causes more depression and anxiety than the disease itself.

Biologic treatment of psoriasis can raise the risk of superficial fungal infections in patients, especially with IL-17 inhibitors.